290 related articles for article (PubMed ID: 19695330)
1. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
Zhou H; Guo M; Bian C; Sun Z; Yang Z; Zeng Y; Ai H; Zhao RC
Biol Blood Marrow Transplant; 2010 Mar; 16(3):403-12. PubMed ID: 19925878
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
4. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.
Hasegawa H; Inoue A; Kohno M; Lei J; Miyazaki T; Yoshie O; Nose M; Yasukawa M
Gene Ther; 2008 Feb; 15(3):171-82. PubMed ID: 17989707
[TBL] [Abstract][Full Text] [Related]
6. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
7. CM-DiI labeled mesenchymal stem cells homed to thymus inducing immune recovery of mice after haploidentical bone marrow transplantation.
Hu KX; Wang MH; Fan C; Wang L; Guo M; Ai HS
Int Immunopharmacol; 2011 Sep; 11(9):1265-70. PubMed ID: 21530684
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease.
Chen W; Li M; Li Z; Yan Z; Cheng H; Pan B; Cao J; Chen C; Zeng L; Xu K
Immunol Lett; 2012 Apr; 143(2):161-9. PubMed ID: 22342854
[TBL] [Abstract][Full Text] [Related]
10. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
11. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.
Yañez R; Lamana ML; García-Castro J; Colmenero I; Ramírez M; Bueren JA
Stem Cells; 2006 Nov; 24(11):2582-91. PubMed ID: 16873762
[TBL] [Abstract][Full Text] [Related]
12. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
13. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
[TBL] [Abstract][Full Text] [Related]
14. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
[TBL] [Abstract][Full Text] [Related]
15. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
16. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model.
Li H; Guo ZK; Li XS; Hou CM; Tang PH; Mao N
Cell Transplant; 2007; 16(1):85-95. PubMed ID: 17436858
[TBL] [Abstract][Full Text] [Related]
17. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
18. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
19. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model.
Kuo YR; Goto S; Shih HS; Wang FS; Lin CC; Wang CT; Huang EY; Chen CL; Wei FC; Zheng XX; Lee WP
Transplantation; 2009 Jun; 87(12):1769-77. PubMed ID: 19543052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
